Treatment of mild to moderate facial melasma with the Lumixyl topical brightening system.
Hantash. Basil M BM; Jimenez. Felipe F
Key Findings
- The 0.01% oligopeptide cream was well tolerated with no reported toxicity.
- All four subjects showed visible improvement in melasma severity.
- One participant achieved full clearance of melasma after six weeks of daily use.
Practical Outcomes
- For DIY skin‑care enthusiasts, a combined regimen of the peptide cream, antioxidant cleanser, 20% glycolic acid lotion, and daily sunscreen may accelerate melasma fading. Start with once‑daily application and monitor for irritation; expect noticeable lightening within a month and possible full clearance in 6 weeks for some users.
Summary
A tiny study (4 people) tested a skin cream called Lumixyl that contains a special 10‑amino‑acid peptide, plus a cleanser, glycolic acid lotion, and sunscreen. All participants saw their melasma (dark facial patches) get lighter, and one person cleared completely in just six weeks.
Abstract
Melasma is a cutaneous disorder associated with an overproduction of melanin by the tyrosinase enzyme. A proprietary oligopeptide (Lumixyl™) was previously shown to competitively inhibit mushroom and human tyrosinase in vitro without the associated cytotoxicity of hydroquinone and to diminish the appearance of facial melasma. The aim of this case study was to determine if the Lumixyl Topical Brightening System (0.01% oligopeptide cream, an antioxidant cleanser, 20% glycolic acid lotion and physical sunscreen) accelerates clearance of mild-to-moderate melasma. All patients showed improvement in their facial melasma with 1 of 4 patients showing complete clearance after just 6 weeks. Results suggest that this regimen may be a useful new tool to treat mild to moderate melasma.
Study Information
pubmed
2012